

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Yang, et al. Case No.: 21541YP
Serial No.: 10/589,406 Art Unit: 1625
Filed: August 11, 2006 Examiner: Rita J. DESAI
For: AMINO HETEROCYCLIC MODULATORS OF
CHEMOKINE RECEPTOR ACTIVITY

The Honorable Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450

RESTRICTION REQUIREMENT

Responsive to the Restriction Requirement dated May 15, 2009, applicants make the following elections.

Group II is elected with traverse to the extent that Group II includes only spiroindenes in which X in formula II is C, but does not include compounds in which X is C wherein R⁷ and R⁸ are substituents that are not connected to form a spiro compound, such as H or a fluorophenyl group, as is required to include Example 1.

If X is defined broadly enough to include both the spiro and non-spiro compounds in which X is C, then the traverse will be withdrawn.


The elected species is Example 3.

The claims that are directed to Group II are claims 2, 4, 6, 9, 10, 13, 15, 17, 19, 23-29, 36, 37, and 42-45.

This is believed to be a complete Response to the Restriction Requirement. This Response is timely, and no fee is due. If a fee is required for this Response to be considered, the PTO is authorized to charge the fee to Deposit Account No. 13-2755.

The Examiner is invited to contact the undersigned at the telephone number provided below, if such would advance prosecution of this case.

Respectfully submitted,

By: 
James L. McGinnis
Reg. No. 34,387
Attorney for Applicants

Merck & Co., Inc.
P.O. Box 2000
Rahway, NJ 07065-0907
(732) 594-0641

Date: June 15, 2009